Abstract
A subset of patients with crescentic glomerulonephritis (CGN) is characterized serologically by the presence of antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody (anti-GBM) called “double positive” disease. The clinical significance of the occurrence of both antibodies is not clear. This study aims to describe the clinical and histologic characteristics and outcomes of CGN in a US cohort of double positive (DP) patients and compare them to patients with anti-GBM disease only or ANCA only (ANCA-associated vasculitis (AAV)). Renal biopsies with a diagnosis of CGN with either pauci-immune or linear immunofluorescence were selected and classified as AAV, anti-GBM disease, or DP based on serologic testing at the time of biopsy. Data on demographics, clinical presentation, treatment, and outcome were obtained by chart review. Six patients with anti-GBM disease, 9 with DP disease, and 18 AAV patients matched for year of diagnosis with DP were identified. Extrarenal disease manifestations were more prominent in the DP patients. The DP patients had severe renal dysfunction at presentation with eight of nine patients requiring dialysis at presentation. Renal biopsy findings of DP patients were similar to anti-GBM disease with majority of glomeruli showing cellular crescents. Eighty-nine percent of patients were treated with immunosuppressive therapy and 78 % with plasmapheresis. At 1 year, all nine DP patients reached end-stage renal disease. We conclude that the DP patients share extrarenal manifestations similar to AAV patients while the renal manifestations resemble anti-GBM patients clinically and histologically. The renal prognosis of DP patients remains poor despite treatment.
Similar content being viewed by others
References
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44
Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042
O'Donoghue DJ, Short CD, Brenchley PE, Lawler W, Ballardie FW (1989) Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 32:251–255
Jia XY, Cui Z, Yang R, Hu SY, Zhao MH (2012) Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury. Clin J Am Soc Nephrol 7:926–933
Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (2010) Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363:343–354
Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, Wang HY (2007) Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 18:1338–1343
Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, Yuan CM (2011) Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22:1946–1952
Jayne DR, Marshall PD, Jones SJ, Lockwood CM (1990) Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965–970
Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C (1997) Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 8:376–385
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66:1535–1540
Bosch X, Mirapeix E, Font J, Borrellas X, Rodriguez R, Lopez-Soto A, Ingelmo M, Revert L (1991) Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36:107–113
Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262
Zhao J, Yang R, Cui Z, Chen M, Zhao MH, Wang HY (2007) Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract 107:c56–c62
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470
Cui Z, Zhao MH, Xin G, Wang HY (2005) Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract 99:c49–c55
Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59–c68
Disclosures
Amar Srivastava, Gautam K Rao, Paul E Segal, and Megha Shah have nothing to disclose while Duvuru Geetha, M.D. served as a consultant and received honoraria from Genentech for educational lectures for sales force.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Srivastava, A., Rao, G.K., Segal, P.E. et al. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 32, 1317–1322 (2013). https://doi.org/10.1007/s10067-013-2268-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2268-5